Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Glioma 12Glioblastoma 6Insulinoma 4Congenital Hyperinsulinism 4Brain Neoplasms 4Neuroendocrine Tumors 3Neuroblastoma 3Hypoglycemia 3Hyperinsulinism 3Recurrence 2Parkinson Disease 2Oligodendroglioma 2Gliosarcoma 2Ependymoma 2Astrocytoma 2Thyroid cancer, medullary 1Sarcoma 1Pheochromocytoma 1Parkinsonian Disorders 1Paraganglioma 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Lewy Body Disease 1Infant, Newborn, Diseases 1Glucose Metabolism Disorders 1Glioma, Subependymal 1Carcinoma, Medullary 1Carcinoid Tumor 1Beckwith-Wiedemann Syndrome 1

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid cancer, medullary × fluorodopa F 18 × Clear all
NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡